AMR Industry Alliance – Statement
Global call for action on drug-resistant infections, 12-13 October 2017, Berlin
Conference organized by Wellcome Trust in partnership with the UK, Ghanaian and Thai governments and the UN Foundation
The AMR Industry Alliance brings together over 100 research-based pharmaceutical, generics, biotech and diagnostic companies and associations, to drive and measure the life-sciences’ industry progress to curb AMR.
In January 2016, the life-sciences industry signed a Declaration on Combatting Antimicrobial Resistance at the World Economic Forum, followed by a Roadmap of several big pharma at the UN High-Level Meeting in September 2016 – a common framework of principles for global measures to curb the development of antibiotic resistance. The “AMR Industry Alliance”, launched in May 2017, now links these two initiatives together and ensures that the signatories collectively deliver on the commitments made.
The vision for the Alliance is to increase accountability in meeting the goals of the Declaration, help better understand what the life-sciences sector is doing to invest in new research to develop new antibiotics and vaccines, and understand the steps they are collectively taking to prevent infection and improve appropriate use of antibiotics.
A first progress report will be launched early 2018, and will track progress in four different areas (Research and Science, Access, Appropriate Use, and Environment), identify gaps and set targets for the future. The Alliance’s reporting will provide timely and concrete insights to inform decision-making at global level and help to assess what are the key hurdles impeding action, and facilitate collaboration between the public and private sectors.
IFPMA (Secretariat of the AMR Industry Alliance)
+41 22 338 32 08